Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Increases By 41.2%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 80,987 shares, a growth of 41.2% from the November 30th total of 57,363 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily volume of 193,362 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 193,362 shares, the short-interest ratio is presently 0.4 days. Currently, 2.1% of the shares of the stock are short sold.

Avalon GloboCare Stock Up 0.8%

ALBT stock opened at $1.34 on Tuesday. The business has a fifty day moving average of $1.63 and a two-hundred day moving average of $2.16. The stock has a market cap of $5.70 million, a price-to-earnings ratio of -0.38 and a beta of -0.11. Avalon GloboCare has a 52-week low of $0.88 and a 52-week high of $11.66.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.06) EPS for the quarter. The firm had revenue of $0.35 million during the quarter.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ALBT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, October 8th. Wall Street Zen lowered Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Avalon GloboCare currently has a consensus rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.